The delisting notice is the dominant event — monitor whether Actinium submits a credible compliance plan by June 26, 2026. A capital raise (dilutive equity offering) is the most likely path to restore equity above $4.0M. The ATNM-400 SNMMI data (May 31-June 2) may provide a near-term trading catalyst, but delisting risk caps upside. If the plan is rejected or no plan is filed, delisting proceedings begin immediately — a binary event.
Price Chart
Executive Summary
Actinium Pharmaceuticals received a delisting notice from NYSE American for failing to meet the $4.0M minimum stockholders' equity standard, reporting only ~$2.3M in equity as of March 31, 2026. The company must submit a compliance plan by June 26, 2026, and has until November 27, 2027 to regain compliance. The filing also includes a press release highlighting preclinical data for its ATNM-400 radioconjugate program at the SNMMI 2026 conference, but this pipeline update does not offset the material delisting risk.
Key Facts
- Received NYSE American delisting notice on May 27, 2026 for non-compliance with Section 1003(a)(ii) requiring $4.0M minimum stockholders' equity
- Stockholders' equity was approximately $2.3 million as of March 31, 2026
- Net losses in each of the last five fiscal years ended December 31, 2025
- Must submit a compliance plan by June 26, 2026; deadline to regain compliance is November 27, 2027
- Stock will trade with a .BC indicator denoting below-compliance status
- Press release also announces preclinical data presentations for ATNM-400 at SNMMI 2026 (May 31-June 2)
- Market cap is approximately $36M with 82% analyst bullish rating
Financial Impact
Stockholders' equity of ~$2.3M is $1.7M below the $4.0M minimum listing standard; failure to regain compliance could lead to delisting, severely reducing liquidity and institutional ownership
Risk Factors
- Failure to submit or gain acceptance of a compliance plan by June 26, 2026 would trigger delisting proceedings
- Regaining compliance likely requires a dilutive capital raise given only $2.3M in equity
- Continued net losses and no approved revenue-generating products create structural listing risk
- Delisting would severely reduce liquidity, institutional ownership, and access to capital markets
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-062935 |
| Document: ea029269101ex99-1.htm | 0001213900-26-062935 |
| Document: 0001213900-26-062935-index-headers.html | 0001213900-26-062935 |
| Document: 0001213900-26-062935-index.html | 0001213900-26-062935 |
| Document: 0001213900-26-062935.txt | 0001213900-26-062935 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 11d ago | DEF 14A | $1.13 | awaiting T+20 | — | $1.42 (+25.66%) |
Oct 15, 2026 12d ago | 8-K | $1.13 | awaiting T+20 | — | $1.42 (+25.66%) |
Aug 14, 2026 10w ago | Press Release | $1.05 $1.25 | ▲ +19.05% | ▲ +21.03% | $1.42 (+35.24%) |
Aug 14, 2026 10w ago | 8-K | $1.05 $1.25 | ▼ −19.05% | ▼ −21.03% | $1.42 (−35.24%) |
Jun 18, 2026 18w ago | 8-K | $1.03 $0.9219 | ▲ +10.50% | ▲ +10.35% | $1.42 (−37.86%) |
May 29, 2026 21w ago | 8-K | $1.18 $0.9800 | ▲ +16.95% | ▲ +15.65% | $1.42 (−20.34%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers